skip to the content

Patients in the ACTEMRA/RoACTEMRA

arm showed significantly less

progression of joint damage

Lithe

Inhibition of Radiographic Progression in RA Patients with DMARD Failure: The LITHE Study

ACTEMRA/RoACTEMRA therapy significantly inhibited the progression of structural joint damage in RA

  • Compared with controls treated with placebo plus MTX, patients in the ACTEMRA/RoACTEMRA 8 mg/kg plus MTX arm had superior ACR20 (56% vs. 25%), ACR50 (36% vs. 10%) and ACR70 (20% vs. 4%) responses (p<0.0001 for each) and more patients achieved DAS28 remission at 1 year (p<0.0001).

DAS28 remission rate increased over time with ACTEMRA/RoACTEMRA

  • Patients in the ACTEMRA/RoACTEMRA 8 mg/kg plus MTX arm also showed significantly less progression of structural joint damage (joint erosion, joint space narrowing and total Sharp-Genant score) and significantly improved physical function (HAQ-DI).

Significant inhibition of RA joint damage with ACTEMRA/RoACTEMRA

  • Inhibition of progression of structural joint damage and improvements in physical function were maintained over 2 years for patients in the ACTEMRA/RoACTEMRA 8 mg/kg plus MTX arm compared with patients who were randomised to placebo plus MTX.

new-LITHE-efficacy-fig

The design of the LITHE study and a summary of baseline characteristics of participants can be found in the Phase III Trials section of the website.

References:
1. RoACTEMRA® (tocilizumab) Summary of Product Characteristics. Roche Registration Limited. August 2011. 2. European Medicines Agency. European Public Assessment Report: RoActemra (EMEA/H-C-955). 2009.